Merck & Co., Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert M. Davis J.D.
- Full Time Employees
- 70,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2000 Galloping Hill Road Kenilworth NJ United States of America 07033
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Company News
2 Incredibly Cheap Big Pharma Stocks to Buy Now
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Activated Polyethylene Glycol Market Report 2024 - Trends, Forecast and Competitive Analysis to 2030, with Profiles of Leading Players NOF, JenKem Technology, Laysan Bio, Merck Creative and PEGWorks
Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Flavonoids Market Report 2024-2032, with Profiles of Key Players Alchem, Bordas, Cayman Chemical, Extrasynthese, Flavon USA, Indena, Inodfine Chemical, Nutralliance, Merck and Quercis Pharma
Merck Is At Support And Should Go Higher (Technical Analysis)
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
Buy 2 October Dogs Of The Dow And Watch 5 More
3 Bargain Stocks Positioned for Gains After Missing 2024's Rally
3 Top Pharma Stocks to Buy in October 2024
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Is Merck Stock a Buy?
Merck (MRK) Stock Sinks As Market Gains: Here's Why
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
When Buffett Meets Bannister